Z
Zijie Liu
Researcher at Peking Union Medical College
Publications - 15
Citations - 480
Zijie Liu is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Epitope & Calanolide A. The author has an hindex of 9, co-authored 14 publications receiving 380 citations.
Papers
More filters
Journal ArticleDOI
Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates
Qidi Wang,Lianfeng Zhang,Kazuhiko Kuwahara,Li Li,Zijie Liu,Taisheng Li,Hua Zhu,Jiangning Liu,Yanfeng Xu,Jing Xie,Hiroshi Morioka,Nobuo Sakaguchi,Chuan Qin,Gang Liu +13 more
TL;DR: Peptide-based vaccines against SARS-CoV could be engineered to avoid ADE via elimination of the S597–603 epitope, an alternative strategy to prepare a safe and effective vaccine for ADE of viral infection by identifying and eliminating epitope sequence-dependent enhancement of viral infections.
Journal ArticleDOI
Highly suppressing wild-type HIV-1 and Y181C mutant HIV-1 strains by 10-chloromethyl-11-demethyl-12-oxo-calanolide A with druggable profile.
Hai Xue,Xiaofan Lu,Purong Zheng,Li Liu,Chunyan Han,Jinping Hu,Zijie Liu,Tao Ma,Yan Li,Lin Wang,Zhiwei Chen,Gang Liu +11 more
TL;DR: In this paper, a new compound, 10-chloromethyl-11-demethyl-12-oxo-calanolide A (20, EC50 = 7.4 nM, SI = 1417), was reported.
Journal ArticleDOI
Cp*CoIII-catalyzed formal [4+2] cycloaddition of benzamides to afford quinazolinone derivatives.
TL;DR: A Cp*CoIII-catalyzed arene C-H bond amidation/annulation of benzamides was developed to afford quinazolinone derivatives in one-pot with high yields and broad substrate scope.
Journal ArticleDOI
A reverse method for diversity introduction of benzimidazole to synthesize H(+)/K(+)-ATP enzyme inhibitors.
TL;DR: A series of 2-[(2-pyridylmethyl)sulfinyl]benzimidazole derivatives were synthesized via a solution phase synthetic route using a reversal method of diversity introduction to identify potent H(+)/K(+)-ATP enzyme inhibitors in vitro.
Journal ArticleDOI
Discovery of 1,4-Benzodiazepine-2,5-dione (BZD) Derivatives as Dual Nucleotide Binding Oligomerization Domain Containing 1/2 (NOD1/NOD2) Antagonists Sensitizing Paclitaxel (PTX) To Suppress Lewis Lung Carcinoma (LLC) Growth in Vivo.
Suhua Wang,Jingshu Yang,Xueyuan Li,Zijie Liu,Youzhen Wu,Guangxu Si,Yiran Tao,Nan Zhao,Xiao Hu,Yao Ma,Yao Ma,Gang Liu +11 more
TL;DR: A 1,4-benzodiazepine-2,5-dione (BZD) derivative is described for the first time that acts as a dual NOD1/NOD2 antagonist and inhibits both nuclear factor κB and mitogen-activated protein kinase (MAPK) inflammatory signaling, thereby sensitizing PTX to suppress Lewis lung carcinoma (LLC) growth.